Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10190082 | 0.82 | CA1 (0.33) | LMNA | |
| SCHEMBL1943173 | 0.75 | L3MBTL1 (0.43) | KDM4EL3MBTL1 | |
| SCHEMBL31363881 | 0.69 | LMNA (0.33) | L3MBTL1LMNA | |
| SCHEMBL15835012 | 0.68 | — | — | |
| SCHEMBL12537601 | 0.66 | KDM4E (0.32) | KDM4EL3MBTL1 | |
| SCHEMBL14080010 | 0.66 | ALDH1A1 (0.40) | KDM4EL3MBTL1 | |
| SCHEMBL2752352 | 0.65 | L3MBTL1 (0.39) | KDM4EL3MBTL1LMNA | |
| SCHEMBL14079934 | 0.63 | KDM4E (0.35) | KDM4EL3MBTL1 | |
| SCHEMBL1476498 | 0.63 | — | — | |
| SCHEMBL31363274 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481566-B2 | 4-Fluoro-6-methyl-1-[1-(tetrahydro-2H-pyran-4-yl)-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; for treatment of psychotic disorders and cognitive impairment | GLAXO GROUP LIMITED (GB) | 2013-07-09 | — | — | US | disclosed |
| US-8288413-B2 | Benzimidazolones which have activity at M1 receptor | GLAXO GROUP LIMITED (GB) | 2012-10-16 | — | — | US | disclosed |
| US-8288412-B2 | Psychological disorders; cognition activators | GLAXO GROUP LIMITED (GB) | 2012-10-16 | — | — | US | disclosed |
| US-8283364-B2 | Psyvhological disorders; cognition activators | GLAXO GROUP LIMITED (GB) | 2012-10-09 | — | — | US | disclosed |
| US-20080306112-A1 | Benzimidazolones Which Have Activity at M1 Receptor | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| US-20080293770-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses In Medicine | GLAXO GROUP LIMITED (GB) | 2008-11-27 | — | — | US | disclosed |
| US-20080255195-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine | GLAXO GROUP LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
| US-20080058378-A1 | Compounds which have activity at M1 receptor and their uses in medicine. | GLAXO GROUP LIMITED (GB) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255195-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine | CHRM1, CHRM2, CHRM5 | KDM4E 4355/4885L3MBTL1 821/4885LMNA 4021/4885 |
| US-20080058378-A1 | Compounds which have activity at M1 receptor and their uses in medicine. | CHRM1, CHRM2, CHRM5 | KDM4E 4204/4885L3MBTL1 681/4885LMNA 3651/4885 |
| US-20080306112-A1 | Benzimidazolones Which Have Activity at M1 Receptor | CHRM1, CHRM2, CHRM4 | KDM4E 4335/4885L3MBTL1 491/4885LMNA 3257/4885 |
| US-20080293770-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses In Medicine | CHRM1, CHRM2, CHRM5 | KDM4E 4368/4885L3MBTL1 812/4885LMNA 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.